CoChat
Cited by 177

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A

Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L., for the ReFacto Phase 3 Study Group · 2003 · Haemophilia

Abstract

Summary.: Background: B‐domain‐deleted recombinant factor VIII (BDDrFVIII) was developed when the B‐domain was found to be redundant for maintaining haemostasis. This allows formulation of the final product without albumin added as a stabilizer. Methods: Three multicentre clinical studies and one pharmacokinetic study were conducted in 218 patients to evaluate the safety and haemostatic efficacy of BDDrFVIII. Results: Previously treated patients (n = 113; median duration, 1711 days; median exposure days, 385; total 98 096 287 IU infused) rated 97–99% of all infusions as good or excellent efficacy. FVIII inhibitor was noted in one patient in the previously treated patient cohort after 113 exposure days. Among 101 previously untreated patients, responses to BDDrFVIII were rated as excellent or good in 92–95% of infusions (median duration, 1413 days; median exposure days, 148; total 12 636 458 IU infused). Thirty‐two previously untreated patients developed inhibitors after a median duration of 12 exposure days (range, 3–49). Sixteen of 32 (50%) patients had low levels (≤ 5 Bethesda units) and 16 had high levels of inhibitors. Inhibitors disappeared in six of 14 (43%) of the high‐level and six of eight (75%) of the low‐level patients who underwent immune tolerance induction therapy. A total of 42 patients underwent surgery and the overall efficacy of BDDrFVIII was rated as excellent or good for 99.6% of infusions. Conclusions: The results of these clinical studies indicate that BBDrFVIII is safe and effective and has haemostatic activity similar to that of full‐length FVIII concentrates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2516.2003.00708.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 177

Metadata

Authors
Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L., & for the ReFacto Phase 3 Study Group
Venue
Haemophilia
Publisher
Wiley
Published
2003-01
Volume
9
Issue
1
Pages
38-49
ISSN
  • 1351-8216 (ISSN-L)
  • 1365-2516
OpenAlex
W2127031749
Cited by
177
References
2
FWCI
5.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. https://app.cochat.ai/papers/10.1046/j.1365-2516.2003.00708.x
The paper
Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L., & for the ReFacto Phase 3 Study Group. (2003). The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. https://doi.org/10.1046/j.1365-2516.2003.00708.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.